Advertisement
Home »

VIVID-1: Mirikizumab Meets Expectations for Patients With Crohn’s Disease

Feb 28, 2024

REFERENCES & ADDITIONAL READING

  1. Ferrante M, et al. Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s disease: results of the treat-through VIVID 1 study. OP05, 19th Congress of ECCO, February 21-24, 2024, Stockholm, Sweden.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement